AcelRx Pharmaceuticals(ACRX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect suf icient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Confer ...